Physician profile
Bruce E Alayof
NPI 1700854213
$6,406.46
in general payments reported to CMS, 2019-2025
30 companies · $953 in 2025
The $953 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $686 · 2021: $602 · 2022: $1,184 · 2023: $1,052 · 2024: $1,095 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,260.75 | 2019-2025 | |
| Amgen INC. | $786.40 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $500.79 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $460.37 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $366.69 | 2019-2024 | |
| Boston Scientific Corporation | $298.98 | 2019-2025 | Watchman Access System, General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.59 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $280.28 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $279.99 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $271.33 | 2019-2025 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.03 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $228.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Heartflow, INC. | $183.12 | 2022-2024 | Ffrct |
| Medtronic, INC. | $162.96 | 2024 | Symplicity G3 |
| Esperion Therapeutics, INC. | $137.86 | 2021-2025 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $132.99 | 2019-2024 | Xarelto |
| Abbott Laboratories | $116.92 | 2023-2025 | Xience Skypoint, Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $82.26 | 2025 | |
| Edwards Lifesciences Corporation | $47.73 | 2020-2025 | Pascal |
| Gilead Sciences, INC. | $46.72 | 2019 | |
| Amarin Pharma, INC. | $43.18 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $35.49 | 2024 | Arcalyst |
| Cvrx, INC. | $23.49 | 2024 | Barostim Neo System |
| Vital Connect, INC | $22.96 | 2025 | Vitalpatch Rtm |
| Lantheus Medical Imaging, INC. | $22.63 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.57 | 2023 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $16.44 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $15.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Alayof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.